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BACKGROUND: Imatinib is a direct and potent inhibitor of the constitutively active tyrosine kinase, breakpoint cluster region-Abelson
(Bcr-Abl), which is central to the pathogenesis of chronic myeloid leukaemia (CML) patients. As such, imatinib has become the front-
line treatment for CML patients. However, the recent emergence of imatinib resistance, commonly associated with point mutations
within the kinase domain, has led to the search for alternative drug treatments and combination therapies for CML.
METHODS: In this report, we analyse the effects of representative members of the novel pro-apoptotic microtubule depolymerising
pyrrolo-1,5-benzoxazepines or PBOX compounds on chemotherapy-refractory CML cells using a series of Bcr-Abl mutant cell lines,
clinical ex vivo patient samples and an in vivo mouse model.
RESULTS: The PBOX compounds potently reduce cell viability in cells expressing the E225K and H396P mutants as well as the highly
resistant T315I mutant. The PBOX compounds also induce apoptosis in primary CML samples including those resistant to imatinib.
We also show for the first time, the in vivo efficacy of the pro-apoptotic PBOX compound, PBOX-6, in a CML mouse model of the
T315I Bcr-Abl mutant.
CONCLUSION: Results from this study highlight the potential of these novel series of PBOX compounds as an effective therapy
against CML.
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Chronic myeloid leukaemia (CML) is caused by breakpoint
cluster region-Abelson (Bcr-Abl), a constitutively active tyrosine
kinase that is the result of the reciprocal translocation between
chromosome 9 and 22, t(9;22), cytogenetically visible as the
Philadelphia chromosome (Deininger et al, 2000). The disease is
thought to originate from the transformation of a haematological
stem cell. Bcr-Abl-positive cells are resistant to apoptosis due to
the continuous activation of signalling pathways downstream of
Bcr-Abl, including the signal transducer and activator transcrip-
tion and phosphatidyl inositol-3 kinase pathways. The majority
of CML patients are diagnosed in the chronic phase that is easily
managed with the novel kinase inhibitor, imatinib (imatinib
mesylate; STI571; Gleevec), which directly targets the oncogenic
Bcr-Abl protein (Deininger et al, 2005). However, some patients
acquire resistance to imatinib and progress to a more aggressive
phase of disease termed the accelerated phase and eventually the
blastic phase, which resembles an acute leukaemia that is largely
resistant to imatinib and rapidly fatal (Deininger and Druker,
2003). Even in patients reaching a complete cytogenetic response,
residual disease remains detectable by PCR techniques suggesting
a continued threat of relapse (O’Hare et al, 2008).
There are many different mechanisms through which patients
become resistant to imatinib, including an increase in the levels
of Bcr-Abl protein expression levels through amplification of the
Bcr-Abl gene, an efflux of imatinib through multi-drug resistant
(MDR) proteins such as P-glycoprotein (P-gp) (Mahon et al, 2000)
and activation of alternative signalling pathways downstream of or
independent to Bcr-Abl (Capdeville et al, 2002). Progression of the
disease can also be associated with additional mutations in
oncogenes such as p53, Ras and retinoblastoma gene. However,
the major mechanism of imatinib resistance is due to mutations at
critical points in the Bcr-Abl gene. These Bcr-Abl mutations can
occur in several functionally distinct regions within the kinase
domain and confer varying degrees of insensitivity to imatinib.
More than 60 different amino-acid substitutions have been found
to date and many of these are mutated at more than one alternative
residue (Apperley, 2007a, b). Mutations fall into two groups, those
that alter amino acids that directly contact imatinib and those that
prevent Bcr-Abl from achieving the inactive conformational state
required for imatinib binding. Of the mutations that result from
amino-acid substitutions, the T315I and E255K mutations are
among the most prevalent (Hughes et al, 2006). Crucially the T315I
mutation is also associated with the highest degree of imatinib
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sresistance, it prevents the formation of a critical hydrogen bond
between imatinib and Bcr-Abl and changes the conformation of
Bcr-Abl to prevent imatinib binding.
These mutations raise the possibility that additional drugs that
target CML cells through alternative mechanisms to Bcr-Abl have the
potential to be successful in treating imatinib-resistant CML patients
(Druker et al,2 0 0 1 ) .A sar e s u l t ,an u m b e ro fs t u d i e sh a v eb e e n
conducted with imatinib in combination with other anticancer
therapeutics including farnesyltransferase inhibitors such as
SCH66336 (lonafarnib) (Peters et al, 2001; Nakajima et al,2 0 0 3 ;
Borthakur et al, 2006), mitogen-activated protein kinase pathway
inhibitors PD184352, PD98059 and U0126 (Yu et al, 2002; Nguyen
et al, 2006) and histone deacetylase inhibitors MS-275 and SAHA
(suberoylanilide hydroxamic acid) among others (Kelly et al,2 0 0 3 ;
Yu et al, 2003; Fiskus et al, 2006a) with varying degrees of success in
in vitro and in vivo animal models. Nilotinib in combination with
LBH589 also produced synergistic results (Fiskus et al, 2006b).
Another approach to overcome imatinib resistance has led to the
development of novel second-generation Bcr-Abl tyrosine kinase
inhibitors. Of these, dasatinib, an orally active, small molecule that
inhibits Bcr-Abl, along with multiple other kinases including the
SRC family kinases (Guilhot et al, 2007) and nilotinib (Tasigna;
Novartis Pharmaceuticals, Basel, Switzerland), a phenyl amino-
pyrimidine analogue of imatinib, have recently been approved by
the FDA for treatment of imatinib-resistant CML patients
(McFarland and Wetzstein, 2009). Although these second-genera-
tion tyrosine kinase inhibitors are effective against many Bcr-Abl
mutants, they are completely ineffective against the T315I mutants.
Although third-line tyrosine kinase inhibitors with activity
against T315I mutants are in clinical trials, it is likely that Bcr-
Abl-independent resistance will arise in advanced CML, suggesting
that agents that target CML cells through alternative mechanisms
to Bcr-Abl have the potential to be successful in treating imatinib-
resistant CML patients (Quinta ´s-Cardama and Cortes, 2008b).
Recently, some members of a novel set of compounds, the
pyrrolo-1,5-benzoxazepine (PBOX) compounds, have been shown to
induce apoptosis in a wide range of solid tumours and haematolo-
gical malignancies (Zisterer et al, 2000). Tubulin has been identified
as the molecular target of these compounds that induce apoptosis in
CML cells by bypassing Bcr-Abl (Mc Gee et al, 2001). The PBOX
compounds have also shown efficacy in ex vivo chronic lymphocytic
leukaemia (CLL) samples (McElligott et al, 2009) and in an in vivo
mouse mammary carcinoma model (Greene et al, 2005). Further-
more, we have also shown that PBOX-6 in combination with imatinib
enhances apoptosis in imatinib-resistant CML cell lines that over-
express the Bcr-Abl protein (Greene et al, 2007). It was therefore of
interest to determine if the PBOX compounds could similarly
induce/enhance apoptosis in CML cells that contain the highly
resistant T315I mutation both in vitro and in vivo.
Using a series of Bcr-Abl mutant cell lines (O’Hare et al, 2008),
we showed the ability of PBOX-6 and PBOX-15 to reduce viability
in cells that contain the imatinib-resistant mutations E225K,
H396P and T315I in vitro. The PBOX compounds also induced
apoptosis in clinical ex vivo CML patient samples including those
resistant to imatinib whereas PBOX-6 reduced tumour load in
a CML mouse model containing the T315I Bcr-Abl mutation.
We conclude that the pro-apoptotic PBOX compounds have
potential as novel therapeutics in the treatment of CML patients,
including those harbouring the notorious T315I mutation.
DESIGN AND METHODS
Cell culture
The murine pro-B cell lines, Baf/3 cells, transfected with either the
native or mutated versions of Bcr-Abl, were previously described
(O’Hare et al, 2008). Baf/3 cell lines were grown in RPMI-1640
(GlutaMAX) medium supplemented with 10% (v/v) fetal bovine
serum (FBS) and 50mgml
 1 penicillin/streptomycin. Parental
Baf/3 cells also required 10ngml
 1 IL-3. Cells were grown in a
humidified environment maintained at 95% O2 and 5% CO2 and
passaged at least twice weekly. Cells were seeded at a density of
2 10
5 cells per ml.
Reagents
RPMI-1640 medium was obtained from Biosciences (Dublin,
Ireland) and FBS from Invitrogen (Paisley, UK). The enhanced
chemiluminescence reagents were supplied by Amersham Bios-
ciences (Buckinghamshire, UK). The BCA reagents were purchased
from Pierce (Rockford, IL, USA) and polyvinylidene difluoride
membranes were sourced from Millipore (Cork, Ireland). Actin and
Bcr-Abl antibodies were obtained from Calbiochem (Nottingham,
UK) whereas the CD45 antibody was from BD Biosciences (Oxford,
UK). Annexin V was obtained from IQ Products (Groningen,
the Netherlands), Lymphoprep from Axis-Shield (Kimbolton,
Cambridgeshire, UK) whereas the binding buffer and AlamarBlue
dye were purchased from Biosource (London, UK). Imatinib was
provided by Novartis Pharmaceuticals. All other reagents were
purchased from Sigma (Tallaght, Dublin, Ireland).
AlamarBlue viability assay
Baf/3 cells expressing native or mutant Bcr-Abl were seeded in
200ml medium in a 96-well plate. Cells were treated and incubated
as required. AlamarBlue (20ml) was added to each well and
incubated at 371C in the dark for 3h. Plates were then read on a
fluorescent plate reader (SpectraMax Gemini; Molecular Devices,
Wokingham, Berkshire, UK) with excitation and emission
wavelengths of 544 and 590nm, respectively. Experiments were
performed in triplicate. A sample containing only reagent and
medium was used as a blank. Vehicle samples were set as 100%
viability from which any decrease in viability was calculated.
Flow cytometry
Baf/3 cells expressing native or mutant Bcr-Abl were seeded in
12-well plates and treated with the designated compound/s or
corresponding vehicle. After the required treatment time samples
were centrifuged at 500g for 5min. Cells were then resuspended
in 100ml ice-cold phosphate-buffered saline (PBS) and ice-cold
70% (v/v) ethanol (1ml) and stored overnight at 41C. Cells were
subsequently pelleted at 800g for 10min and resuspended in 200ml
PBS. RNase A (10mgml
 1) and propidium iodide (100mgml
 1)
were then added to each sample and incubated for 30min at 371C
in the dark. Cell-cycle analysis was performed at 488nM using a
Becton Dickinson (Franklin Lakes, NJ, USA) FACS Calibur flow
cytometer. Apoptosis was determined by quantification of the
pre-G1 peak. CellQuest was then used to analyse the data of 10000
gated cells once cell debris had been excluded. The data was stored
as frequency histograms (Riccardi and Nicoletti, 2006).
Western blot analysis
SDS–polyacrylamide gel electrophoresis was performed as pre-
viously described (Bright et al, 2009). Briefly, whole-cell lysates
were prepared in Laemmli buffer and run on an 8% gel.
Equal protein loading was ensured by performing a BCA protein
determination assay. Samples were then transferred to polyviny-
lidene difluoride membranes overnight, blocked in 5% (w/v)
marvel in Tris-buffered saline (pH 7.6)/0.05% Tween 20, incubated
for 1h with an anti-Abl or anti-Actin mAb, washed, incubated for
1h with a horseradish peroxidase-linked secondary Ab and washed
again. Blots were developed using enhanced chemiluminescence
and an automated developer (Fuji X-ray film processor,
Fuji-Glasnevin, Dublin, Ireland).
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sEx vivo CML patient samples and annexin V staining
Peripheral blood (10ml) was collected with informed consent from
newly diagnosed treatment naive (n¼4) or blast crisis imatinib-
resistant CML patients (n¼2) in EDTA-anticoagulant tubes.
Ethical approval for all work carried out on ex vivo CML patient
samples was obtained from the St. James’s Hospital and Adelaide
and Meath incorporating the National Children’s Hospital Ethics
Committee. Fresh blood was diluted 1:3 with unsupplemented
RPMI medium and carefully added to half the equivalent volume
of Lymphoprep. Samples were centrifuged at 750g for 30min to
form a Ficoll gradient. The white buffy layer containing the white
blood cells (WBCs) (or peripheral blood mononuclear cells) was
carefully removed, diluted to a volume of 50ml with medium and
centrifuged again for 10min at 650g. White blood cells were then
seeded at a density of 1 10
6 cells per 1ml medium in RPMI
medium supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine
and 50mgml
 1 penicillin/streptomycin. After the required incuba-
tion, cells were centrifuged at 650g for 5min, incubated in the dark
at room temperature for 10min with anti-CD45 antibody,
centrifuged as before, washed in 1  annexin V binding buffer
(1ml), centrifuged, labelled with Annexin V antibody on ice for
15min in the dark, washed and finally resuspended them in 500ml
Annexin V binding buffer. Leukaemic cells were then identified
and gated by flow cytometry based on their low to medium side
scatter and low CD45 expression, and apoptosis was analysed by
annexin V staining (Lacombe et al, 1997).
Mice
Specific pathogen-free 6- to 8-week-old adult female BALB/c-nu/nu
mice were purchased from Harlan Laboratories (Cambridgeshire,
UK). Mice were housed in sterile individually ventilated cages,
food and water were provided ad libitum, in accordance with the
standard operating procedures set down in SI 17/94 of the
European Union. Mice were acclimatised for 1 week before the
initiation of any in vivo experiments. Animals were killed by CO2 if
found to be in distress (hunching, failure to groom etc.) or if
tumour volume exceeded 10% of mouse bodyweight. Ethical
approval was obtained by the BioResources Committee, Trinity
College, Dublin.
In vivo tumour studies
The in vivo antitumour efficacy of PBOX-6 was examined using a
Baf/3 xenograft containing the T315I mutant of Bcr-Abl in a
BALB/c mouse model. Female BALB/c-nu/nu mice were inoculated
subcutaneously (s.c.) into the right flank with 3 10
6 Baf/3 cells in
the log phase of growth. After 8 days, we observed that tumours
had reached approximately 4mm in diameter and we randomly
divided mice into two groups. A stock solution of PBOX-6 was
prepared at a concentration of 15mgml
 1 in 1:1 ethanol/cremophor
EL. When required, this was then diluted 1 in 5 in sterile PBS to
give a final concentration of 7.5mgkg
 1 or 0.15mg per mouse. The
treatment group (n¼6) received an intratumoural (i.t.) injection
(Williams et al, 2007; Shah et al, 2009) of PBOX-6 once daily for
the duration of the experiment starting on day 8. Control mice
(n¼6) received a single daily i.t. injection of 50ml of the equivalent
vehicle also starting on day 8. Tumour growth was measured every
second day with a sterile vernier calliper. The long (L) and short
(S) axes were recorded, and tumour volume (V) was calculated
using the following equation as described previously (Beck et al,
2003).
V ¼
S2 L
2
Mice were killed by CO2 asphyxiation at the experimental end
point or if found to be under any excess duress.
Statistical analysis
The software Prism GraphPad (La Jolla, CA, USA) was used to
carry out statistical analysis when comparing two samples using
the Student’s paired (ex vivo studies) or unpaired (in vivo studies)
t-test. For illustrative purposes, the P-values are presented as
Po0.05, * and Po0.01, ** respectively.
RESULTS
Mutations in the Bcr-Abl gene confer varying degrees of
resistance to imatinib in transfected Baf/3 cell lines
The status of the Bcr-Abl protein in parental and transfected
Baf/3 cells was confirmed by subjecting untreated cells to
SDS–polyacrylamide gel electrophoresis and western blotting.
Results confirmed the presence of the Bcr-Abl protein in native
cells and each of the mutant cell lines and absence of the protein in
the parental, non-transformed Baf/3 cells (Figure 1A).
An AlamarBlue assay was used to show the varying effects of
imatinib on each cell line. As expected, imatinib displayed the
highest level of toxicity against the native cell line followed by the
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Figure 1 Mutant Baf/3 cell lines containing the Bcr-Abl protein display
varying degrees of resistance to imatinib when compared with the native
cells. (A) Baf/3 cells were seeded during the log phase of growth and
incubated for 24h. Samples were prepared for SDS–polyacrylamide gel
electrophoresis and run on an 8% gel. Polyvinylidene difluoride membranes
were incubated overnight with an anti-Bcr-Abl mAb. Actin is shown as a
loading control. Results are representative of three independent experi-
ments. (B) Cells were treated for 48h with a vehicle (Veh) (0.01 %
DMSO) or a range of imatinib concentrations (50nM–10mM) in a 96-well
plate. After the incubation period, we added AlamarBlue dye (20ml) to
each well and incubated samples for 3h. Cells were subsequently analysed
for cell viability. Values represent the mean±s.e.m. of three independent
experiments performed in triplicate. ND, not determined.
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sH396P, E255K and finally the T315I mutant cell lines. Specifically,
native cells were found to have an IC50 value of 658nM towards
imatinib. H396P cells were 2.9 times more resistant to imatinib
than native cells whereas E255K cells were 11.1 times more
resistant. The IC50 value for T315I cells could not be determined as
these cells were found to be completely resistant to imatinib even
at concentrations as high as 10mM (Figure 1B).
PBOX compounds significantly reduce cell viability and
induce apoptosis in imatinib-resistant and native Baf/3 cell
lines
The pro-apoptotic PBOX compounds were found to significantly
reduce cell viability in all cell lines examined. Viability was
reduced to 27.2±2.4, 25.2±0.8, 41.5±8.1 and 48.7±6.1% in
native, T315I, H396P and E255K cells treated with 25mM PBOX-6
(Figure 2A). PBOX-15 also significantly reduced cell viability in all
the Bcr-Abl mutant Baf/3 cells. Specifically, PBOX-15 (10mM)
reduced viability to 29.2±1.9, 28.1±5.1, 42.1±4.5 and 40.7±4.6%
in native, T315I, H396P and E255K, respectively (Figure 2B).
As the PBOX compounds caused similar effects against all the
mutations tested, it was decided to focus our attention on the
T315I mutation that conferred the highest degree of resistance to
imatinib. Flow cytometry results showed that PBOX-6 and
PBOX-15 induced similar levels of apoptosis (Figure 2C) in both
native and T315I cells. PBOX-6 also caused a similar number of
cells to undergo a sustained G2/M arrest, with the percentage of
cells in the G2/M phase increasing from 23.7±2.1 and 16.9±2.1%
to 43.7±4.0 and 37.5±7.5% in WT and T315I cells, respectively
(Figure 2D).
The PBOX compounds were also evaluated for their effects on
parental non-transfected Baf/3 cells, whereas the compounds
did induce some toxicity on these cells (data not shown) it should
be noted that the cells had been artificially stimulated using IL-3 to
produce actively dividing cells. However, B cells in vivo are not
actively cycling and are therefore unlikely to be affected by the
compounds.
PBOX compounds induce apoptosis in ex vivo samples
from newly diagnosed and imatinib-resistant blast crisis
phase CML patients
The advent of cell lines has allowed us to gain insight into many
molecular signalling pathways; they are a useful tool to help
develop novel therapeutic anticancer agents. However as cell lines
have been engineered to continuously and consistently divide, they
do not fully represent primary leukaemia cells. For this reason, it is
necessary to confirm the effects of potentially novel therapeutics
found in cell lines on ex vivo patient samples. For this, we obtained
informed consent from a cohort of newly diagnosed and treatment
naive CML patients along with those that had refractory disease.
Annexin V staining was then used to identify apoptotic cells.
Patient samples 1–4 were newly diagnosed CML patients who
subsequently responded well to either imatinib or nilotinib, none
have since progressed to later stages of CML. Patient samples 5
and 6 were obtained from imatinib- and dasatinib-insensitive
patients in blast crisis (Table 1). Patient 5 tested 100% positive
for the T315I mutation at time of death that occurred approxi-
mately 1 month after sample collection, whereas patient 6 who is
currently on nilotinib treatment tested 100% positive for the F317l
mutation at the time of sample collection and had a minor T315I
mutant clone.
White blood cells were isolated from freshly obtained blood
samples, seeded and treated for 72h with a PBOX compound
(25mM PBOX-6 or 10mM PBOX-15) or 250nM imatinib, a
physiologically relevant concentration of STI571. Leukaemic cells
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Figure 2 PBOX-6 and PBOX-15 reduce cell viability and induce apoptosis equipotently in native and T315I Baf/3 cell lines. Native and Bcr-Abl mutant
Baf/3 cells were seeded during the log phase of growth and treated for 48h with a vehicle (1% (v/v) ethanol) (Veh) or with the indicated concentrations of
PBOX-6 or PBOX-15 (P6, P15). After the incubation period, we assessed cells for (A and B) cell viability by the AlamarBlue viability assay, (C) apoptosis by
quantification of the pre-G1 peak and (D) the percentage of cells in the G2/M phase. Values represent the mean±s.e.m. of three independent experiments
performed in triplicate.
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swere identified by their low to medium side scatter and low CD45
expression after annexin V staining (Figure 3A).
Collectively, when all samples were combined, PBOX-6 induced
24.7±5.0% apoptosis (P-value: 0.0050,**) whereas PBOX-15
induced 39.5±5.8% apoptosis (P-value: 0.0059,**) compared with
background levels of apoptosis of 13.4±5.5% in control samples.
There was no significant difference between the control and the
imatinib-treated samples that underwent 18.2±7.7% apoptosis
(Figure 3B). This may have been due to the inclusion of the two
imatinib-resistant patient samples. No individual sample showed a
lack of response to either PBOX-6 or PBOX-15.
PBOX-6 administration significantly inhibits tumour
growth in a CML mouse model of the imatinib-resistant
T315I mutants
Five- to six-week-old female BALB/c-nude mice were inoculated
s.c. into the right flank with 3 10
6 Baf/3-T315I cells in the log
phase of growth. Tumours started to appear by day 5/6 and were
measurable by day 8. Mice were divided into groups with small-,
medium- and larger-sized tumours and then further randomly
divided into two groups (n¼6) to ensure the average tumour size
was equal for both groups. One group received daily i.t. injections
of 7.5mgkg
 1 PBOX-6 whereas the other group received a vehicle
(10% (v/v) ethanol and 10% (v/v) cremophor EL in PBS).
Results showed that PBOX-6 did not adversely affect weight. In
fact, both groups put on a small amount of weight during the
experiment increasing from 14.7±0.7 and 14.8±0.6g to 16.5±0.8
and 16.5±0.3g in control and PBOX-treated groups, respectively.
This would be expected with healthy mice of such an age
(Figure 4A). Close inspection of mice also ensured that no mouse
suffered any form of distress such as failing to groom, hunching.
Tumour growth was measured every second day, the long (L)
and short (S) axes were recorded, and tumour volume (V)
calculated using the following equation: V¼(S
2 L)/2 (Beck et al,
2003). Injections were initiated on day 8 when there was no
significant difference in tumour volume between the control and
the PBOX-treated groups. By day 10, PBOX-6 had significantly
reduced tumour growth when compared to control group. Tumour
burden was continuously and significantly inhibited up until the
experimental end point (Figure 4B). Statistical analysis was
performed using an unpaired Student’s t-test.
At the experimental end point, day 18, mice were killed by
CO2 asphyxiation and a splenectomy was performed. The
vehicle-treated group showed gross enlargement of spleens, or
splenomegaly a clinical symptom of advanced disease, when
compared to the PBOX-6-treated group, with a 3.7-fold increase in
weight from 163.3±39.51 to 608.7±105.3mg (P-value: 0.0027,**)
(Figure 4C). This is likely to be due to the reduced tumour burden
of PBOX-treated animals.
DISCUSSION
Our group has recently developed a novel set of compounds
known as the PBOXs that actively induce apoptosis in numerous
haematological cancers and solid tumours (Zisterer et al, 2000,
Table 1 Characteristics of CML patients in ex vivo study
No. Sex Age Disease status CML treatment Current status
1 M 46 Newly diagnosed Imatinib Currently on imatinib, CCR within first year treatment
2 F 31 Newly diagnosed Imatinib Currently on imatinib, CCR within first year treatment
3 M 26 Newly diagnosed Nilotinib (as part of clinical trial) Currently on nilotinib, MCR in first 3 months treatment
4 F 42 Newly diagnosed Nilotinib (as part of clinical trial) Currently on nilotinib, MCR in first 3 months treatment
5 F 73 Blast crisis Failed imatinib+dasatinib treatment Deceased, 100% positive for T315I mutation at time of death
6 F 62 Blast crisis Failed imatinib+dasatinib treatment Currently on nilotinib, 100% positive for F317I
mutation and minor T315I clone at time of sample collection
Abbreviations: CCR¼a complete cytogenetic response means that no blood or bone marrow cells contain the Ph chromosome; CML¼chronic myeloid leukaemia; M¼male;
F¼female; MCR¼a major (or partial) cytogenetic response the presence of less than 35% Bcr-Abl-positive cells. Relevant medical and personal data were obtained from newly
diagnosed and imatinib-resistant CML patients enrolled in an ex vivo PBOX study carried out in St. James’s Hospital, Dublin 8 in collaboration with Dr. Eibhlin Conneally and
Professor Mark Lawler. Information obtained included the sex of the patient, age at diagnosis and a short description of their medical and CML-specific treatment.
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Figure 3 Isolation of leukaemic cells from CML patient blood samples.
White blood cells were isolated from the fresh peripheral blood of CML
patients (n¼6) by Ficoll gradient. Cells were seeded at a density of 1 10
6
cells per ml in 24-well plates and treated with a vehicle (Veh) (1% (v/v)
ethanol or 0.0025% (v/v) DMSO), 10mM PBOX-15 (P15), 25mM PBOX-6
(P6) or 250nM imatinib for 72h. Cells were then labelled with an anti-
CD45 antibody and FITC-annexin V and analysed by flow cytometry.
Leukaemic cells were identified and gated based on their low to medium
side scatter and low CD45 expression. (A) A representative dot plot of
CD45-stained vehicle-treated cells is shown. (B) Percentage of cells
undergoing apoptosis as determined by annexin-V-positive staining.
Experiments were performed in duplicate. Statistical analysis was
performed using the Student’s paired t-test, ** Po0.01.
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s2001; Mc Gee et al, 2004; Mulligan et al, 2006). Representative
compounds have recently been shown to induce apoptosis in
ex vivo CLL patient samples including samples that are composed
of cells with poor prognostic markers such as fludarabine-resistant
cells with chromosomal deletions in 17p (McElligott et al, 2009).
Furthermore, an in vivo study by our group has previously
shown PBOX-6 to exhibit antitumour activity in a murine breast
tumour model (Greene et al, 2005) highlighting their potential as
novel anticancer agents. Recent data also suggest the PBOX
compounds show activity in MDR cell lines by bypassing P-gp
(Nathwani et al, 2009).
The tyrosine kinase inhibitor imatinib has revolutionised CML
treatment since its regulatory approval in 2001 (Deininger and
Druker, 2003). In spite of this success, disease progression into a
fatal acute leukaemia still occurs. Disease progression is commonly
associated with mutations within the kinase domain of Bcr-Abl
that result in varying degrees of resistance to imatinib, these
mutations have been identified as the major mechanism of
acquired imatinib resistance. Therefore, the search for alternative
drug treatments capable of overcoming such resistance is crucially
important (O’Hare et al, 2007). For this reason, we analysed the
effects of the PBOX compounds on CML cells harbouring such
mutations.
The amino-acid mutations chosen for this study represented
several functionally distinct kinase domain regions, including the
P-loop (E255K), the site of a hydrogen bond with imatinib (T315I)
and the activation loop (H396P) (Griswold et al, 2006). Transfected
cells were first subjected to analysis by western blot and confirmed
the presence of the Bcr-Abl protein. A viability assay showed that
the mutant Bcr-Abl cells, displayed as expected, varying degrees of
resistance to imatinib of between 2.9- and 11.1-fold for H396P and
E255K cells, respectively, when compared to native cells. T315I
cells showed complete resistance to concentrations of imatinib as
high as 10mM.I C 50 values and resistance fold difference could not
therefore be determined for these cells. However, a previous report
suggests an IC50 value of 18mM for Bcr-Abl-T315I cells treated with
imatinib (Chen et al, 2006).
In comparison to the wide range of effects of imatinib on the
viability of Bcr-Abl mutants, PBOX-6 and PBOX-15 reduced the
viability to a similar extent in all four cell lines. The clones
harbouring these mutations, particularly the prevalent mutations
E255K and T315I, have been shown to exist before imatinib
treatment (Roche-Lestienne et al, 2002, 2003; Shah et al, 2002;
Hofmann et al, 2003; Kreuzer et al, 2003) and are associated with
enhanced kinase activities and proliferation rates (Yamamoto et al,
2004; Griswold et al, 2006). Mutations such as E255K are also
associated with significantly shorter survival rates than other
mutations, regardless of their sensitivity to imatinib (Griswold
et al, 2006), resulting in a more aggressive phenotype. This
highlights the importance of the PBOX compounds in overcoming
these aggressive mutations. The apoptotic effects of the PBOX
compounds have also been shown to be irreversible, a recent study
on the CML cell line, K562, has shown the PBOX compounds to
continue to induce apoptosis 24h after cells have been washed free
of the compounds (Bright et al, 2010).
One of the most common Bcr-Abl mutations found in CML
patients is the T315I mutation. Many imatinib-resistant mutants
are sensitive to second-generation inhibitors such as dasatinib and
nilotinib; however, the T315I mutation remains insensitive to both
drugs (O’Hare et al, 2007; Quinta ´s-Cardama and Cortes, 2008b).
Thus, it was decided to concentrate our efforts on the T315I
mutation for further analysis. Results showed PBOX-6 and
PBOX-15 to induce similar levels of apoptosis in native and
T315I mutant cells, suggesting that these agents are capable of
overcoming imatinib resistance irrespective of Bcr-Abl genotype.
Although there are numerous reports of novel compounds
effective at inducing apoptosis in T315I-expressing cells in the
literature, many are at a pre-clinical stage such as ON012380 a
non-competitive ATP inhibitor (Gumireddy et al, 2005), SGX393 a
direct Bcr-Abl inhibitor (O’Hare et al, 2008) and the histone
deacetylase inhibitor LAQ824 (Weisberg et al, 2004). Compounds
that have displayed activity against the T315I mutants in clinical
trials include the aurora kinase inhibitor MK-0457 (Giles et al,
2007) and homoharringtonine that inhibits protein synthesis
(Quinta ´s-Cardama and Cortes, 2008a). Other compounds currently
undergoing clinical assessment but whose antitumour activity in
patients has yet to be fully determined include the histone
deacetylase inhibitors SAHA and LBH589, the farnesyltransferase
inhibitor BMS-214662 and the aurora kinase inhibitors PHA-739358
and AT-9283 among others (Tanaka and Kimura, 2008; Quinta ´s-
Cardama and Cortes, 2008b). However, to date no compound with
activity against the T315I mutation has made it through trials and
onto the clinical market.
Although the effects of the PBOXs on Bcr-Abl mutations in vitro
is clear, these results needed to be confirmed in ex vivo patient
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Figure 4 Administration of PBOX-6 significantly inhibits tumour growth
and prevents gross spleen enlargement in an in vivo mouse model of CML
harboring the T315I mutation. Five- to six-week-old female BALB/c-nude
(nu/nu) mice were inoculated s.c. into the right flank with 3 10
6 Baf/3-
Bcr-Abl-T315I cells in the log phase of growth. When tumours had reached
a diameter of B4mm (day 8), mice were randomly divided into two
treatment groups (n¼6) and received daily i.t. injections of PBOX-6 (P6)
(7.5mgkg
 1) or a vehicle (Veh) (10% (v/v) cremophor, 10% (v/v) ethanol
in PBS). (A) Mice were weighed every 4 days and at the experimental end
point (day 18). (B) Tumour growth was measured every second day, the
long (L) and short (S) axes were recorded, and tumour volume (V)
calculated using the equation: V¼(S
2 L)/2 (Beck et al., 2003). (C) Mice
were killed on day 18, spleens were removed and weighed. Statistical
analysis was performed using the Student’s unpaired t-test, *Po0.05;
**Po0.01.
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ssamples, critically important in predicting a clinical response to
potential anticancer drugs. Of the newly diagnosed patients
enlisted for PBOX evaluation, all ex vivo samples analysed (4 out
of 4) displayed a significant increase in apoptosis after PBOX-6
and PBOX-15 treatment when compared with imatinib and control
treatments. Half of these patients (2 out of 4) are currently on the
front-line treatment for chronic phase CML, imatinib treatment,
with the other half on nilotinib treatment as part of a clinical trial.
These results suggest a potential role for the pro-apoptotic PBOX
compounds in the treatment of newly diagnosed CML patients.
Similar enhancements in apoptosis were also observed in two
imatinib-resistant ex vivo samples both of whom tested positive for
the T315I mutation. Although the low levels of the T315I mutation
in patient 6 are unlikely to have contributed significantly to in
vitro resistance, this patient also tested 100% positive for the F317l
mutation, another highly imatinib-resistant mutation, suggesting
the PBOX compounds also successfully induce apoptosis in cells
harbouring this mutation. Although the number of primary
samples obtained is limited and no firm conclusions can be drawn
from the data of just two imatinib-resistant patients, these positive
results do warrant a larger study assessing the effects of the PBOX
compounds on further imatinib-insensitive primary samples to be
undertaken.
Notably, the PBOX compounds do not display cytotoxicity in
blood samples obtained from healthy volunteers (Mc Gee et al,
2004; Greene et al, 2007; McElligott et al, 2009). Furthermore, a low
level of vasorelaxing activity and a lack of inhibition of
nitrendipine binding, both measures of calcium antagonism
suggest a general lack of cardiotoxicity of the PBOX compounds
(DMZ, unpublished data). A lack of in vivo toxicity was also
observed in unchallenged Balb/c mice administered for 8 days with
PBOX-6 as determined by analysis of the haematology parameters
of platelets, WBCs and red blood cells when compared to vehicle-
treated mice (DMZ, unpublished data).
The PBOX compounds are not just specific for Bcr-Abl-positive
cells but are also specific for a wide variety of cancerous cells.
The molecular target of the PBOX compounds has recently
been identified as tubulin and differences between the tubulin
properties of cancer and non-cancer cells may therefore be
responsible for the preference of the compounds for cancer cells.
The compounds have been shown to bind to a novel, as yet
uncharacterised binding site on tubulin (Mulligan et al, 2006) and
work is currently underway to characterise this binding site using
X-ray crystallography. This will give further insight into the exact
mechanism of action and specificity of the compounds.
After the demonstration that the PBOX compounds induce
apoptosis in vitro and in ex vivo patient samples, we next sought to
determine the effects of the PBOX compounds in an in vivo CML
xenograft model. The xenotransplant model has also been
successfully used for the preliminary pre-clinical drug testing of
SCH66336 and SXG393 (Peters et al, 2001; O’Hare et al, 2008) and
although this model is not without limitations it does enable the
effective testing of the compounds on the T315I mutation in vivo.
Although PBOX-15 showed more potent activity in primary
samples, PBOX-6 was chosen as a representative PBOX compound
for in vivo testing as it has previously been shown to restrict
tumour growth in an in vivo mouse mammary carcinoma (Greene
et al, 2005). It remains to be seen whether PBOX-15 shows activity
in vivo. Female Balb/c nude mice were injected s.c. with Baf/3
T315I CML cells and randomly divided into two treatment groups.
Results showed that PBOX-6 significantly impeded tumour growth
while also preventing gross spleen enlargement when compared to
mice receiving vehicle injections. Mice did not experience weight
loss or exhibit any signs of distress during PBOX treatment
suggesting PBOX-6 to be a viable anticancer agent in vivo.
Although the control group also appeared to gain some weight
throughout the experiment, this may have been due to the increase
in spleen weight rather than natural growth.
Although tumour growth was significantly reduced, the tumour
mass did still increase over the duration of the experiment;
however, the results from this and previous research suggest the
true potential of the PBOX compounds in vivo could lie in their
combination with other anticancer compounds, recent data have
shown the ability of the PBOXs to synergise with other compounds
including imatinib and the CDK1 inhibitor flavopiridol. (Greene
et al, 2007; Bright et al, 2009, 2010). Future studies looking at the
activity of the PBOX compounds in combination with these agents
in vivo are planned, as are advanced models that more readily
replicate the disease in vivo, such as the retroviral CML mouse
model. Ongoing work with a collaborating laboratory, looking at
the design and synthesis of ‘second-generation’ more potent PBOX
compounds could potentially further increase the activity of the
compounds.
In conclusion, the PBOX compounds significantly reduced the
cell viability of CML cells lines harbouring the E225K, H396P and
T315I Bcr-Abl mutations. Both PBOX-15 and PBOX-6 significantly
increased the number of cells undergoing apoptosis in native and
T315I cells in vitro and in ex vivo patient samples whereas PBOX-6
also significantly reduced tumour burden in a mouse xenograft
model. These results underline the potential of the PBOX
compounds in the clinical treatment of CML patients including
those who develop the highly resistant T315I mutant.
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